MOSCOW, Feb 13 (PRIME) -- The revenue of Russian biopharmaceutical company Nanolek, a subsidiary of state nanotechnology company Rusnano, tripled on the year to 2.6 billion rubles in 2017, the company said in a statement on Tuesday without providing accounting standards.
The company’s production at the plant in the Kirov Region rose 20% to 8.1 million packs last year.
“The company’s plans for 2018 include strengthening of positions in directions that we chose – vaccines, medicines for treatment of orphan diseases, and retrovirus therapy. The company continues investment in portfolio development, in clinical tests, and in registration of new medicines. The combined investment portfolio will exceed 350 million rubles in 2018,” the company said quoting its President Vladimir Khristenko.
(58.0171 rubles – U.S. $1)
End
|
|
